A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

February 29, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

May 31, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

GENA-104A16

GENA-104A16 is administered as a 1 hour (h) \[-5 minutes and +60 minutes , i.e., 55-120 minutes as window time\] as intravenous (IV) infusion on q2w.

Trial Locations (1)

Seoul National University Hospital, Seoul